Trials / Recruiting
RecruitingNCT06902857
Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV)
Prospective Observational Study on the Predictive Value of Cardiac Damage Markers High-sensitivity Cardiac Troponin I (Hs-cTnI), N-terminal Pro-B-natriuretic Peptide (NT-proBNP) and Soluble Suppression of Tumorigenesis-2 (sST2) for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV).
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,002 (estimated)
- Sponsor
- Istituto Nazionale di Ricovero e Cura per Anziani · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- —
Summary
The Diabetes-CV study is an observational study designed to assess the prognostic value of serum cardiac damage markers high-sensitivity cardiac troponin I (hs-cTnI), N-terminal pro-B-natriuretic peptide (NT-proBNP), and soluble suppression of tumorigenesis-2 (sST2) in predicting mortality, major adverse cardiovascular events, and diabetic complications in patients with type 2 diabetes.
Detailed description
This single-center, investigator-initiated, prospective observational study aims to evaluate the prognostic value of serum cardiac damage markers such as high-sensitivity cardiac troponin I (hs-cTnI), N-terminal pro-B-natriuretic peptide (NT-proBNP) and soluble suppression of tumorigenesis-2 (sST2) in subjects with type 2 diabetes. The study will utilize clinical and laboratory data from patients attending the Diabetology Unit at the IRCCS INRCA Hospital in Ancona (Italy), including both study-specific data and information extracted from routine outpatient medical records.
Conditions
Timeline
- Start date
- 2024-04-18
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
- First posted
- 2025-03-30
- Last updated
- 2025-04-03
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06902857. Inclusion in this directory is not an endorsement.